All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How do recent systemic approvals influence treatment selection for patients with psoriatic disease?
By Ella Dixon
How do recent systemic approvals influence treatment selection for patients with psoriatic disease?
During the Psoriasis Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA.
Listen to this video as a podcast here:
How do recent systemic approvals influence treatment selection for patients with psoriatic disease?
Your opinion matters
1 vote - 63 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox